Table 3.

Patient-reported resource use, expenses, and caregiver support in 12-month questionnaire (n = 635)

	CDS (n = 334)		Usual care (n = 301)
	n	(%)	n	(%)	P-value
Number of patients who reported at least one ER visit	45	(13.5)	42	(14.0)	0.934
Number of ER visits
Mean (SD)	0.3	(1.0)	0.4	(1.8)	0.536
Median (Q1, Q3)	0.0	(0.0, 0.0)	0.0	(0.0, 0.0)
Number of patients who reported at least one hospitalization	22	(6.6)	21	(7.0)	0.763
Number of times admitted to hospital
Mean (SD)	0.1	(0.4)	0.1	(0.3)	0.799
Median (Q1, Q3)	0.0	(0.0, 0.0)	0.0	(0.0, 0.0)
Number of patients who reported at least one family physician visit	91	(27.2)	101	(33.6)	0.212
Number of times visited family physician
Mean (SD)	0.9	(2.2)	1.1	(2.6)	0.168
Median (Q1, Q3)	0.0	(0.0, 0.0)	0.0	(0.0, 0.0)
Number of patients who reported at least one specialist visit	158	(47.3)	141	(46.8)	0.756
Type of specialist
AF clinic visit/Anticoagulation nurse	9	(2.7)	7	(2.3)	0.816
Cardiologist	121	(36.2)	105	(34.9)	0.792
Internal medicine	43	(12.9)	48	(15.9)	0.476
Complementary Health	6	(1.8)	1	(0.3)	0.265
Number of patients with at least one NOAC medication	136	(40.7)	128	(42.5)	0.407
Number of patients with NOAC coverage
Nova Scotia Pharmacare	41	(30.1)	38	(29.7)	0.894
Private Insurance	68	(50.0)	68	(53.1)	0.494
Self	27	(19.9)	18	(14.8)	0.390
Not documented	0	(0.0)	4	(2.3)
Number of patients who reported use of other medications
St John’s Wort	2	(0.7)	1	(0.3)	0.632
Aspirin	53	(15.9)	38	(12.6)	0.582
Voltaren	29	(8.7)	24	(8.0)	0.643
Naproxen	2	(0.7)	1	(0.3)	0.633
Ibuprofen	6	(1.8)	4	(1.3)	0.650
Number of patients who reported work loss due to AF	8	(2.4)	10	(3.3)	0.661
Number of patients who reported hiring a paid caregiver	5	(1.5)	4	(1.3)	0.898

Abbreviations: AF Atrial fibrillation, SD Standard deviation, Q1 First quartile, Q3 Third quartile, ER Emergency room, NOAC Novel oral anticoagulant, CDS Clinical decision support

NOAC medications include Apixaban (Eliquis), Dabigatran (Pradaxa), Rivaroxaban (Xarelto), Edoxaban (Savaysa)